Buspirone/zolmitriptan

Buspirone/zolmitriptan
Buspirone (top) and
zolmitriptan (bottom)
Combination of
BuspironeSerotonin 5-HT1A receptor agonist
ZolmitriptanSerotonin 5-HT1B and 5-HT1D receptor agonist
Clinical data
Other namesZolmitriptan/buspirone; AV-2860; AV2860; JM-010; JM010
Routes of
administration		Oral[1]
Drug classNon-selective serotonin 5-HT1 receptor agonist

Buspirone/zolmitriptan, also known by its developmental code names AV-2860 and JM-010, is a combination of buspirone, a serotonin 5-HT1A receptor partial agonist, and zolmitriptan, a serotonin 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F receptor agonist, which is under development for the treatment of drug-induced dyskinesia, specifically levodopa-induced dyskinesia in people with Parkinson's disease.[1][2][3][4][5] It is taken orally.[1] The drug is under development by Contera Pharma and Bukwang Pharmaceutical.[1][4] As of November 2024, it is in phase 2 clinical trials for treatment of drug-induced dyskinesia.[1][4] Buspirone/zolmitriptan has failed to meet its endpoints in phase 2 trials.[2]

See also

References

  1. ^ a b c d e "Buspirone/Zolmitriptan". AdisInsight. 3 November 2024. Retrieved 19 January 2026.
  2. ^ a b Al-Kassmy J, Alsalmi M, Kang W, Palayew M, Huot P (October 2025). "Recent and on-going trials for the treatment of levodopa-induced dyskinesia: a review of the clinical trial databases". Neurodegenerative Disease Management. 15 (5): 235–244. doi:10.1080/17582024.2025.2528557. PMC 12456213. PMID 40616455.
  3. ^ LeWitt PA, Stebbins GT, Christensen KV, Tan R, Pretorius A, Thomsen M (March 2024). "Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study". Movement Disorders. 39 (3): 613–618. doi:10.1002/mds.29713. PMID 38314643.
  4. ^ a b c "Delving into the Latest Updates on JM-010 with Synapse". Synapse. 30 August 2025. Retrieved 19 January 2026.
  5. ^ Rubio-Beltrán E, Labastida-Ramírez A, Haanes KA, van den Bogaerdt A, Bogers AJ, Zanelli E, et al. (December 2019). "Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan". British Journal of Pharmacology. 176 (24): 4681–4695. doi:10.1111/bph.14832. PMC 6965684. PMID 31418454.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.